NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque ...

Focus on including foods high in calories, protein, and nutrients into your loved one’s diet when they are experiencing ...

With the field of HER2-positive breast cancer evolving rapidly, how will practice change in the clinic after the recent ...

The fundraise will help advance a cancer therapy that’s already shown early promise in people whose cancers haven’t responded ...

Genmab Announces Financial Results for the First Half of 2025August 7, 2025 Copenhagen, Denmark; Interim Report for the First Half Ended June 30, 2025HighlightsEpcoritamab advancing to earlier lines ...

Despite progress on several clinical programs and tighter cost controls, there was a major decline in cash reserves, with cash and cash equivalents (GAAP) decreasing from $49.0 million as of December ...

Relay Therapeutics beat analyst estimates for both GAAP revenue and earnings per share in Q2 2025. The company reported continued clinical advancement of its lead asset RLY-2608, with new positive ...

Researchers have found that a common tool used by clinicians for predicting kidney failure could be underestimating the risk ...

Key opinion leader event and pancreatic cancer clinical data validate decision to engage with regulators on plans for a registration-enabling study New members of the ...

Epkinly with Rituxan and Revlimid, compared to Rituxan and Revlimid alone, reduced risk of progression or death by 79%.

Since 1990, the global incidence of early-onset cancer has risen by 80 percent. Oncologists share what's behind the rising ...

Revenue: Revenue was $0.7 million for the second quarter of 2025, as compared to $0 for the second quarter of 2024.